Plan ahead
Plan ahead of these events, and schedule time with us!
We can help you:
Understand
Understand the landscape in seconds for the targeted therapy of your choice.
Book a demo
To book a live demo to show you how this works specifically to your questions.
Events Beacon will be attending
2nd Cell Therapy for Autoimmune Disease Summit
December 2-4, 2024 | Philadelphia, PA
Accelerate the Clinical Development of CAR-T, Treg & NK-Based Therapies with Improved Efficacy, Durability & Safety to Revolutionize Curative Care for Chronic Autoimmune Disease.
The Cell Therapy for Autoimmune Disease Summit is an unparalleled, pioneering event that unites leading experts and stakeholders in this exciting emerging field. This groundbreaking summit is a platform for sharing and discussing the latest advances in pre-clinical, translational, and clinical development across various cell types including CAR-T, Tregs, and NKs.
With 75+ attendees, 30+ world-class speakers including the likes of Cabaletta, Cartesian, Abata, and Bristol Myers Squibb delving into everything from new pre-clinical and clinical data, developing therapies with a high safety profile, innovative trial design, translational biomarkers, and over 6 hours of dedicated networking, ensure you join us to revolutionize the treatment landscape for chronic autoimmune diseases.
Our Immune Tolerance Research Lead, Rachel Hourigan, joins the line-up, setting the scene, with a comprehensive review of the past, present & future of the cell therapy autoimmune landscape, at 9:00 a.m. Find out more of her session details here; this is one not to be missed!
Find out more
Personalized Cancer Vaccine Summit 2024
December 3 – 5, 2024 | Boston, MA
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer real hope for every patient with a cure for cancer.
The Personalized Cancer Vaccine Summit returns to Boston for the third year bringing together the top industry players developing individualized approaches across several modalities
Beacon Cancer Vaccine’s expert research analyst, Gloria Castro, will be taking to the stage to deliver an overview of the current drug and trial landscape, delving into the shifting landscape of disease focus in preclinical vs. clinical drug development and see how personalized cancer vaccines are breaking ground in precision medicine. Gain insights into therapeutic class distribution and trial phases driving these innovative treatments forward. Find out the full details today.
Join us and 80+ key stakeholders at the ultimate learning and networking forum to help advance your patient-centric pipelines toward the clinic and regulatory approval.
8th DDR Inhibitors Summit 2025
January 28 – 30, 2025 | Boston, MA
The 8th Annual DDR Inhibitors Summit in Boston this January will bring together top organizations and many more to collaborate, share insights, and shape the future of DDR therapeutics for cancer treatment.
Large pharma like Novartis, AstraZeneca, and Merck are driving the next wave of DDR inhibitor innovation with precision biomarker strategies, cutting-edge ATR and WEE1 inhibitor combinations, and next-gen PARP inhibitors. Meanwhile, emerging biotech leaders, including IDEAYA and ForX Therapeutics, are advancing the field with AI-driven platforms and genetic screening to uncover new targets and develop selective inhibitors.
Beacon’s DDR Lead Research Analyst, Dasha Kaloujskaia, will join the expert speaker faculty to deliver “A Comprehensive Overview of DDR Therapies: Key Insights & Combination Strategies. ” We will review the DDR landscape as of 2024, share a case study on PARP combinations in key indications, and discuss emerging trends to watch for in 2025. This session begins at 4:00 p.m. on Day One and you can discover further details here.
Find out more
